M Lein

Summary

Affiliation: Humboldt University
Country: Germany

Publications

  1. ncbi request reprint [New serum markers of bone metastasis in prostate carcinoma]
    M Lein
    Klinik für Urologie, Charite Universitatsmedizin Berlin, Charite Campus Mitte, Chariteplatz 1, 10117 Berlin
    Urologe A 46:1087-8. 2007
  2. pmc Translating molecular medicine into clinical tools: doomed to fail by neglecting basic preanalytical principles
    Klaus Jung
    Department of Urology, Charite Universitatsmedizin Berlin, Campus Mitte, Schumannstr 20 21, 10117 Berlin, Germany
    J Transl Med 7:87. 2009
  3. pmc Artificial neural network (ANN) velocity better identifies benign prostatic hyperplasia but not prostate cancer compared with PSA velocity
    Carsten Stephan
    Department of Urology, Charite Universitatsmedizin Berlin, Germany
    BMC Urol 8:10. 2008
  4. pmc ADAM9 is highly expressed in renal cell cancer and is associated with tumour progression
    Florian R Fritzsche
    Institute of Surgical Pathology, Universitatsmedizin Berlin, Berlin, Germany
    BMC Cancer 8:179. 2008
  5. pmc Brain-type and liver-type fatty acid-binding proteins: new tumor markers for renal cancer?
    Angelika Tölle
    Department of Urology, Charite Universitatsmedizin Berlin, Berlin, Germany
    BMC Cancer 9:248. 2009
  6. ncbi request reprint A multicenter clinical trial on the use of alpha1-antichymotrypsin-prostate-specific antigen in prostate cancer diagnosis
    M Lein
    Department of Urology, University Hospital Charite, Humboldt University, Berlin, Germany
    Prostate 47:77-84. 2001
  7. ncbi request reprint A multicenter clinical trial on the use of complexed prostate specific antigen in low prostate specific antigen concentrations
    Michael Lein
    Department of Urology, University Hospital Charite, Humboldt University Berlin, Germany
    J Urol 170:1175-9. 2003
  8. ncbi request reprint Serial markers of bone turnover in men with metastatic prostate cancer treated with zoledronic Acid for detection of bone metastases progression
    Michael Lein
    Department of Urology, Charité Hospital Berlin Mitte, University Medicine Berlin, Berilin, Germany
    Eur Urol 52:1381-7. 2007
  9. ncbi request reprint The new synthetic matrix metalloproteinase inhibitor (Roche 28-2653) reduces tumor growth and prolongs survival in a prostate cancer standard rat model
    Michael Lein
    Department of Urology, University Hospital Charite, Humboldt University Berlin, 10098 Berlin, Germany
    Oncogene 21:2089-96. 2002
  10. ncbi request reprint Complications, urinary continence, and oncologic outcome of 1000 laparoscopic transperitoneal radical prostatectomies-experience at the Charité Hospital Berlin, Campus Mitte
    Michael Lein
    Department of Urology, Charité Hospital Berlin, Campus Mitte, University Medicine Berlin, Germany
    Eur Urol 50:1278-82; discussion 1283-4. 2006

Collaborators

Detail Information

Publications104 found, 100 shown here

  1. ncbi request reprint [New serum markers of bone metastasis in prostate carcinoma]
    M Lein
    Klinik für Urologie, Charite Universitatsmedizin Berlin, Charite Campus Mitte, Chariteplatz 1, 10117 Berlin
    Urologe A 46:1087-8. 2007
  2. pmc Translating molecular medicine into clinical tools: doomed to fail by neglecting basic preanalytical principles
    Klaus Jung
    Department of Urology, Charite Universitatsmedizin Berlin, Campus Mitte, Schumannstr 20 21, 10117 Berlin, Germany
    J Transl Med 7:87. 2009
    ..Otherwise a lost of translation, as discussed in JTM journal, seems to be inevitable...
  3. pmc Artificial neural network (ANN) velocity better identifies benign prostatic hyperplasia but not prostate cancer compared with PSA velocity
    Carsten Stephan
    Department of Urology, Charite Universitatsmedizin Berlin, Germany
    BMC Urol 8:10. 2008
    ..To validate an artificial neural network (ANN) based on the combination of PSA velocity (PSAV) with a %free PSA-based ANN to enhance the discrimination between prostate cancer (PCa) and benign prostate hyperplasia (BPH)...
  4. pmc ADAM9 is highly expressed in renal cell cancer and is associated with tumour progression
    Florian R Fritzsche
    Institute of Surgical Pathology, Universitatsmedizin Berlin, Berlin, Germany
    BMC Cancer 8:179. 2008
    ..We evaluated the expression of ADAM9 on protein and transcript level in a clinico-pathologically characterized renal cell cancer cohort...
  5. pmc Brain-type and liver-type fatty acid-binding proteins: new tumor markers for renal cancer?
    Angelika Tölle
    Department of Urology, Charite Universitatsmedizin Berlin, Berlin, Germany
    BMC Cancer 9:248. 2009
    ..We examined the level of brain-type (B) and liver-type (L) FABP mRNA and the protein expression profiles of both FABPs in renal cell carcinoma...
  6. ncbi request reprint A multicenter clinical trial on the use of alpha1-antichymotrypsin-prostate-specific antigen in prostate cancer diagnosis
    M Lein
    Department of Urology, University Hospital Charite, Humboldt University, Berlin, Germany
    Prostate 47:77-84. 2001
    ..The aim was to evaluate the clinical performance of alpha(1)-antichymotrypsin prostate-specific antigen (PSA-ACT) for early diagnosis of prostate cancer (PCa) in a multicenter trial...
  7. ncbi request reprint A multicenter clinical trial on the use of complexed prostate specific antigen in low prostate specific antigen concentrations
    Michael Lein
    Department of Urology, University Hospital Charite, Humboldt University Berlin, Germany
    J Urol 170:1175-9. 2003
    ..The determination of complexed prostate specific antigen (cPSA) has been suggested to be promising for prostate cancer (PCa) diagnosis. In a multicenter trial we evaluate the diagnostic use of PSA forms in the low total PSA (tPSA) range...
  8. ncbi request reprint Serial markers of bone turnover in men with metastatic prostate cancer treated with zoledronic Acid for detection of bone metastases progression
    Michael Lein
    Department of Urology, Charité Hospital Berlin Mitte, University Medicine Berlin, Berilin, Germany
    Eur Urol 52:1381-7. 2007
    ..This study assessed the usefulness of serial measurements of bone turnover markers in men with metastatic prostate cancer treated with zoledronic acid to detect disease progression...
  9. ncbi request reprint The new synthetic matrix metalloproteinase inhibitor (Roche 28-2653) reduces tumor growth and prolongs survival in a prostate cancer standard rat model
    Michael Lein
    Department of Urology, University Hospital Charite, Humboldt University Berlin, 10098 Berlin, Germany
    Oncogene 21:2089-96. 2002
    ..A significantly prolonged survival of Ro 28-2653-treated rats was also demonstrated. Selective inhibition of MMP activity is a novel therapeutic approach, which bears promise for studies in patients with prostate cancer...
  10. ncbi request reprint Complications, urinary continence, and oncologic outcome of 1000 laparoscopic transperitoneal radical prostatectomies-experience at the Charité Hospital Berlin, Campus Mitte
    Michael Lein
    Department of Urology, Charité Hospital Berlin, Campus Mitte, University Medicine Berlin, Germany
    Eur Urol 50:1278-82; discussion 1283-4. 2006
    ..This study was initiated to evaluate LRP with regard to complications, urinary continence, and oncologic outcome...
  11. ncbi request reprint A multicenter clinical trial on the use of (-5, -7) pro prostate specific antigen
    Michael Lein
    Departments of Urology, University Hospital Charite, Humboldt University Berlin, Schumannstrasse 20 21, 10098 Berlin, Germany
    J Urol 174:2150-3. 2005
    ..The determination of pro prostate specific antigen (proPSA) forms has been suggested to be promising in prostate cancer diagnosis. In this multicenter trial we evaluated the diagnostic usefulness of (-5, -7) proPSA...
  12. ncbi request reprint Ratio of alpha 1-antichymotrypsin--prostate specific antigen to total prostate specific antigen in prostate cancer diagnosis
    M Lein
    Department of Urology, University Hospital Charite, Humboldt University Berlin, Schumannstrasse 20 21, D 10098 Berlin, Germany
    Anticancer Res 20:4997-5001. 2000
    ....
  13. ncbi request reprint Comparison of the clinical validity of free prostate-specific antigen, alpha-1 antichymotrypsin-bound prostate-specific antigen and complexed prostate-specific antigen in prostate cancer diagnosis
    M Lein
    Department of Urology, University Hospital Charite, Humboldt University, Berlin, Germany
    Eur Urol 39:57-64. 2001
    ....
  14. ncbi request reprint [Molecular forms of prostate-specific antigen and human kallikrein 2 as possible indicators in prostatic carcinoma diagnosis]
    M Lein
    Klinik für Urologie, Universitatsklinikum Charite, Medizinische Fakultat, Humboldt Universitat zu Berlin
    Urologe A 39:313-23. 2000
    ..The other molecular PSA forms and hK2 are still objects of research and their diagnostic significance needs to be evaluated in more extensive clinical trials...
  15. ncbi request reprint Synthetic inhibitor of matrix metalloproteinases (batimastat) reduces prostate cancer growth in an orthotopic rat model
    M Lein
    Department of Urology, Charite University Hospital, Humboldt University, Berlin, Germany
    Prostate 43:77-82. 2000
    ....
  16. ncbi request reprint Matrix-metalloproteinases and their inhibitors in plasma and tumor tissue of patients with renal cell carcinoma
    M Lein
    Department of Urology, University Hospital Charite, Humboldt University, Berlin, Germany
    Int J Cancer 85:801-4. 2000
    ..In plasma, MMP-9 concentrations were significantly higher in RCC patients than in healthy controls, MMP-2 and TIMP-2 concentrations were higher in healthy controls and TIMP-1 concentrations were not different...
  17. ncbi request reprint Ratio of free or complexed prostate-specific antigen (PSA) to total PSA: which ratio improves differentiation between benign prostatic hyperplasia and prostate cancer?
    K Jung
    Department of Urology, University Hospital Charite, Humboldt University, Schumannstrasse 20 21, D 10098 Berlin, Germany
    Clin Chem 46:55-62. 2000
    ....
  18. ncbi request reprint Molecular forms of prostate-specific antigen in malignant and benign prostatic tissue: biochemical and diagnostic implications
    K Jung
    Department of Urology, University Hospital Charite, Humboldt University, Schumannstrasse 20 21, D 10098 Berlin, Germany
    Clin Chem 46:47-54. 2000
    ..The patterns of the intracellular PSA isoforms in malignant and benign prostatic tissue have been studied as potential molecular reasons for this phenomenon...
  19. ncbi request reprint [New biomarkers and application of multivariate models for detection of prostate cancer]
    C Stephan
    Klinik für Urologie, Charite Universitatsmedizin Berlin, Berlin, Germany
    Aktuelle Urol 40:221-30. 2009
    ..There is generally an advantage to include the new markers and clinical data as additional parameters to PSA and %fPSA within ANN and LR models. Results of these studies and also unexpected pitfalls are discussed in this review...
  20. ncbi request reprint Molecular forms of prostate-specific antigen in serum with concentrations of total prostate-specific antigen <4 microg/L: are they useful tools for early detection and screening of prostate cancer?
    K Jung
    Department of Urology, University Hospital Charite, Humboldt University, Berlin, Germany
    Int J Cancer 93:759-65. 2001
    ..The ratios could be useful in assessing the risk of PCa in the individual and therefore in deciding on prostate biopsy for final diagnosis...
  21. ncbi request reprint Analytical performance and clinical validity of two free prostate-specific antigen assays compared
    K Jung
    Department of Urology, University Hospital Charite, Humboldt University, Berlin, Germany
    Clin Chem 42:1026-33. 1996
    ..Discrimination limits of 16% (CanAg assay), and 15% (Immulite assay) are recommended for f-PSA%...
  22. ncbi request reprint [New serum markers in prostate carcinoma and their application to artificial neural networks]
    C Stephan
    Klinik für Urologie, Charite Universitatsmedizin Berlin, Charite Campus Mitte, Chariteplatz 1, 10117, Berlin
    Urologe A 46:1084-6. 2007
  23. ncbi request reprint Receiver-operating characteristic as a tool for evaluating the diagnostic performance of prostate-specific antigen and its molecular forms--What has to be considered?
    K Jung
    Department of Urology, University Hospital Chariteé, Humboldt University, Berlin, Germany
    Prostate 46:307-10. 2001
    ....
  24. doi request reprint Bone turnover markers as predictive tools for skeletal complications in men with metastatic prostate cancer treated with zoledronic acid
    Michael Lein
    Department of Urology, Charité Hospital Berlin, University Medicine Berlin, Berlin, Germany
    Prostate 69:624-32. 2009
    ....
  25. ncbi request reprint Different stability of free and complexed prostate-specific antigen in serum in relation to specimen handling and storage conditions
    K Jung
    Department of Urology, University Hospital Charite, Humboldt University Berlin, Germany
    Clin Chem Lab Med 38:1271-5. 2000
    ....
  26. ncbi request reprint Quantification of matrix metalloproteinases and tissue inhibitors of metalloproteinase in prostatic tissue: analytical aspects
    K Jung
    Department of Urology, University Hospital Charite, Humboldt University, Berlin, Germany
    Prostate 34:130-6. 1998
    ..The determination of these components needs a special strategy of tissue preparation. This analytical problem has not been considered for prostatic tissue...
  27. ncbi request reprint Matrix metalloproteinases 1 and 3, tissue inhibitor of metalloproteinase-1 and the complex of metalloproteinase-1/tissue inhibitor in plasma of patients with prostate cancer
    K Jung
    Department of Urology, University Hospital Charite, Humboldt University Berlin, Germany
    Int J Cancer 74:220-3. 1997
    ..TIMP-1 concentrations were correlated with staging but not with grading. Our results point towards plasma TIMP-1 concentration as a potential marker of malignant progression of PCa...
  28. ncbi request reprint Increased analytical sensitivity of RT-PCR of PSA mRNA decreases diagnostic specificity of detection of prostatic cells in blood
    W Henke
    Klinik und Poliklinik fur Urologie, Universitatsklinikum Charite, Medizinische Fakultat der Humboldt Universitat zu Berlin, Germany
    Int J Cancer 70:52-6. 1997
    ..Further development of this diagnostic method requires the introduction of the quantitative PCR which may make possible discrimination between prostatic and non-prostatic source of PSA mRNA by quantification...
  29. ncbi request reprint Plasma osteopontin in comparison with bone markers as indicator of bone metastasis and survival outcome in patients with prostate cancer
    Azizbek Ramankulov
    Department of Urology, Charite University Medicine Berlin, Campus Charite Mitte, Berlin, Germany
    Prostate 67:330-40. 2007
    ....
  30. ncbi request reprint Prostate-specific antigen, its molecular forms, and other kallikrein markers for detection of prostate cancer
    Carsten Stephan
    Department of Urology, University Hospital Charite, Humboldt University Berlin, Berlin, Germany
    Urology 59:2-8. 2002
  31. ncbi request reprint Treatment of varicocele with reference to age: a retrospective comparison of three minimally invasive procedures
    S Beutner
    Department of Urology, Carl Thiem Hospital, Cottbus, Germany
    Surg Endosc 21:61-5. 2007
    ....
  32. ncbi request reprint The novel synthetic inhibitor of matrix metalloproteinases Ro 28-2653 induces apoptosis in Dunning tumor cells
    D Mangoldt
    Department of Urology, University Hospital Charite, Humboldt University, Berlin, Germany
    Apoptosis 7:217-20. 2002
    ..This effect of Ro 28-2653 on apoptosis was dose- and time-dependent increasing with concentration between 10 and 100 microg/ml as well as with time of treatment between 24 and 48 h...
  33. ncbi request reprint [An artificial neural network as a tool in risk evaluation of prostate cancer. Indication for biopsy with the PSA range of 2-20 microg/l]
    C Stephan
    Klinik und Poliklinik fur Urologie, Universitatsklinikum Charite, Humboldt Universitat, Berlin
    Urologe A 42:1221-9. 2003
    ..The use of an ANN at PSA 2-20 microg/l enhances the specificity and sensitivity of %fPSA by 9-39%. The application of an ANN based on %fPSA and clinical data improves the diagnostic performance compared to %fPSA only...
  34. ncbi request reprint Blood specimen collection methods influence the concentration and the diagnostic validity of matrix metalloproteinase 9 in blood
    K Jung
    Department of Urology, University Hospital Charite, Humboldt University Berlin, Schumannstrasse 20 21, D 10098 Berlin, Germany
    Clin Chim Acta 314:241-4. 2001
    ..To clarify whether the sampling process also influences the diagnostic validity of MMPs, MMP-9 measurements were performed in plasma and serum samples of patients with prostate carcinoma and renal cell cancer...
  35. ncbi request reprint [Fast-track laparoscopic radical prostatectomy]
    O Gralla
    Klinik für Urologie, Klinikum der Universität zu Köln, Kerpener Strasse 62, Koln, Germany
    Urologe A 47:712-7. 2008
    ..By using a multimodal fast-track concept in patients undergoing laparoscopic radical prostatectomy, we aimed to investigate the feasibility of this procedure after elective surgery and a possible discharge 3 days postoperatively...
  36. ncbi request reprint Enhanced inhibitory effect of the matrix metalloproteinase inhibitor Ro 28-2653 in combination with estramustine and etoposide on the prostate carcinoma in the rat Dunning orthotopic tumor model
    Claudia Abramjuk
    Department of Urology, University Hospital Charite, Humboldt University, Schumannstrasse 20 21, 10098, Berlin, Germany
    Cancer Chemother Pharmacol 59:275-82. 2007
    ....
  37. ncbi request reprint Elevated plasma osteopontin as marker for distant metastases and poor survival in patients with renal cell carcinoma
    Azizbek Ramankulov
    Department of Urology, University Hospital Charite, Charite University Medicine Berlin, Campus Charite Mitte, Schumannstrasse 20 21, 10098 Berlin, Germany
    J Cancer Res Clin Oncol 133:643-52. 2007
    ..To evaluate diagnostic and prognostic significance of plasma osteopontin (OPN) in patients with renal cell carcinoma (RCC)...
  38. doi request reprint [What is most important is what comes across : Urological guidelines from the target group's point of view]
    J Busch
    Klinik für Urologie, Charite Universitatsmedizin Berlin, Chariteplatz 1, 10117, Berlin, Deutschland
    Urologe A 49:75-80. 2010
    ..The effect of German urologic guidelines has not been evaluated so far. Therefore, we aimed to systematically investigate the acceptance, use, and quality of the published guidelines from a user's perspective...
  39. pmc Novel compounds with antiangiogenic and antiproliferative potency for growth control of testicular germ cell tumours
    B Nitzsche
    Department of Physiology, Charite Universitatsmedizin Berlin, Campus Benjamin Franklin, Arnimallee 22, Berlin 14195, Germany
    Br J Cancer 103:18-28. 2010
    ..g., VEGFR, PDGFR), we identified two compounds (HP-2 and HP-14) with antiangiogenic and antiproliferative potency, which were evaluated in endothelial cell models and TGCT cells...
  40. doi request reprint [Adjuvant and neoadjuvant drug therapy for prostate cancer]
    K Miller
    Klinik und Hochschulambulanz für Urologie, Charite Universitatsmedizin Berlin, Hindenburgdamm 30, 12200, Berlin, Deutschland
    Urologe A 47:1460-4. 2008
    ..For high-risk patients, long-term (2-3 years) adjuvant LHRH analog treatment is indicated...
  41. doi request reprint [Testicular cancer - explanatory models for high cisplatin chemosensibility and new therapeutic options]
    J Ebbing
    Charite Universitatsmedizin Berlin, Campus Benjamin Franklin, Berlin
    Aktuelle Urol 39:429-35. 2008
    ..Furthermore, the current data on alternative chemotherapies as well as of molecular, molecular-genetic and pharmacogenetic therapeutic concepts are explored. Data were obtained from researches in Medline of the Pubmed database...
  42. ncbi request reprint S100A8, S100A9, and the S100A8/A9 complex in circulating blood are not associated with prostate cancer risk-A re-evaluation study
    Stefan Ludwig
    Department of Urology, Charite University Medicine Berlin, Campus Charite Mitte, Berlin, Germany
    Prostate 67:1301-7. 2007
    ..To evaluate the diagnostic performance of plasma S100A8, S100A9, and the S100A8/A9 complex as novel markers to discriminate between benign and malignant prostatic diseases as recently suggested for S100A9...
  43. ncbi request reprint Toward metrological traceability in the determination of prostate-specific antigen (PSA): calibrating Beckman Coulter Hybritech Access PSA assays to WHO standards compared with the traditional Hybritech standards
    Carsten Stephan
    Department of Urology, Charite Universitatsmedizin Berlin, Berlin, Germany
    Clin Chem Lab Med 46:623-9. 2008
    ....
  44. ncbi request reprint Determination of non-alpha1-antichymotrypsin-complexed prostate-specific antigen as an indirect measurement of free prostate-specific antigen: analytical performance and diagnostic accuracy
    Sebastian Wesseling
    Department of Urology, University Hospital Charite, Humboldt University, D 10098 Berlin, Germany
    Clin Chem 49:887-94. 2003
    ..We evaluated nACT-PSA and its ratio to total PSA (tPSA) as alternatives to free PSA (fPSA) and its ratio to tPSA in differentiating prostate cancer (PCa) and benign prostatic hyperplasia (BPH) in patients with tPSA of 2-20 micro g/L...
  45. doi request reprint Prostate specific antigen density to predict prostate cancer upgrading in a contemporary radical prostatectomy series: a single center experience
    Ahmed Magheli
    Department of Urology, Charité Hospital Berlin, Campus Mitte, University Medicine Berlin, Berlin, Germany
    J Urol 183:126-31. 2010
    ..We investigated the value of pretreatment prostate specific antigen density to predict Gleason score upgrading in light of significant changes in grading routine in the last 2 decades...
  46. doi request reprint [New developments in minimally invasive urology: NOTES (Natural Orifice Transluminal Endoscopic Surgery) and LESS (Laparo-Endoscopic Single-Site Surgery) in urology]
    S Deger
    Klinik und Poliklinik für Urologie der Charité, Universitatsmedizin Berlin, Berlin
    Aktuelle Urol 40:23-6. 2009
    ..In the next few years, comparative studies between these techniques and conventional laparoscopy can be expected...
  47. doi request reprint A [-2]proPSA-based artificial neural network significantly improves differentiation between prostate cancer and benign prostatic diseases
    Carsten Stephan
    Department of Urology, Charite Universitatsmedizin Berlin, Berlin, Germany
    Prostate 69:198-207. 2009
    ....
  48. ncbi request reprint Comparison of two different artificial neural networks for prostate biopsy indication in two different patient populations
    Carsten Stephan
    Department of Urology, Charite Universitatsmedizin Berlin, Campus Charite Mitte, Berlin, Germany
    Urology 70:596-601. 2007
    ..The applicability of independently trained ANN and logistic regression (LR) models to different populations regarding the composition (screening versus referred) and different PSA assays has not yet been tested...
  49. ncbi request reprint Serum (-5, -7) proPSA for distinguishing stage and grade of prostate cancer
    Carsten Stephan
    Departments of Neurology, Universitätsmedizin Charité Berlin, CCM, Germany
    Anticancer Res 27:1833-6. 2007
    ..ProPSA has been suggested for the detection of preferentially aggressive prostate cancer (PCa). We report on the use of proPSA and free PSA to enhance preoperative staging and grading...
  50. doi request reprint Discordant total and free prostate-specific antigen (PSA) assays: does calibration with WHO reference materials diminish the problem?
    Carsten Stephan
    Department of Urology, Charite Universitatsmedizin Berlin, Berlin, Germany
    Clin Chem Lab Med 47:1325-31. 2009
    ..1 microg/L should be considered for WHO calibrated assays in order to achieve the same sensitivity/specificity profile as with a cut-off of 4 microg/L in traditionally calibrated assays. The %fPSA cut-offs could be retained...
  51. doi request reprint Bone turnover markers as predictors of mortality risk in prostate cancer patients with bone metastases following treatment with zoledronic acid
    Klaus Jung
    Department of Urology, University Hospital Charite, Berlin, Germany
    Eur Urol 59:604-12. 2011
    ..Clinical data have limited validity for predicting the survival of prostate cancer (PCa) patients with bone metastases. There is a need to improve the predictive evidence both for clinicians and patients...
  52. ncbi request reprint 20-25% lower concentrations of total and free prostate-specific antigen (PSA) after calibration of PSA assays to the WHO reference materials--analysis of 1098 patients in four centers
    Carsten Stephan
    Department of Urology, Charite Universitatsmedizin Berlin, Germany
    Int J Biol Markers 24:65-9. 2009
    ..To examine the potential clinical implications of the recalibration of total prostate-specific antigen (PSA) and free PSA (fPSA) assays to the World Health Organization (WHO) standard materials...
  53. ncbi request reprint ADAM9 expression is a significant and independent prognostic marker of PSA relapse in prostate cancer
    Florian R Fritzsche
    Institute of Pathology, Charite Universitatsmedizin Berlin, Berlin, Germany
    Eur Urol 54:1097-106. 2008
    ....
  54. ncbi request reprint New markers and multivariate models for prostate cancer detection
    Carsten Stephan
    Department of Urology, Charite Universitatsmedizin Berlin, Germany
    Anticancer Res 29:2589-600. 2009
    ..There is generally an advantage to including new markers and clinical data as additional parameters to PSA and % fPSA within ANN and LR models. The results and unexpected pitfalls of these studies are shown...
  55. doi request reprint Plasma matrix metalloproteinase-7 as a metastatic marker and survival predictor in patients with renal cell carcinomas
    Azizbek Ramankulov
    Department of Urology, Charite University Hospital, Berlin, Germany
    Cancer Sci 99:1188-94. 2008
    ..81, 95% CI, 2.77-12.2; P < 0.0001) as independent determinants of cancer-related survival outcomes. In conclusion, increased plasma MMP-7 could be related to metastatic disease and poor prognosis in patients with RCC...
  56. doi request reprint An artificial neural network for five different assay systems of prostate-specific antigen in prostate cancer diagnostics
    Carsten Stephan
    Institute for Medical Informatics, Charlité Universitätsmedzin Berlin, Berlin, Germany
    BJU Int 102:799-805. 2008
    ..To compare separate prostate-specific antigen (PSA) assay-specific artificial neural networks (ANN) for discrimination between patients with prostate cancer (PCa) and no evidence of malignancy (NEM)...
  57. doi request reprint Gene promoter methylation and its potential relevance in early prostate cancer diagnosis
    Isabel Steiner
    Institute of Pathology, Charite Universitatsmedizin Berlin, Berlin, Germany
    Pathobiology 77:260-6. 2010
    ....
  58. ncbi request reprint Divergent effects of taurolidine as potential anti-neoplastic agent: inhibition of bladder carcinoma cells in vitro and promotion of bladder tumor in vivo
    Claudia Abramjuk
    Department of Urology, University Hospital Charite Berlin, 10098 Berlin, Germany
    Oncol Rep 22:409-14. 2009
    ..In contrast to other authors we could not find any anti-proliferative effect, we actually showed that instillation into the rat urinary bladder enhanced tumor growth...
  59. doi request reprint Benign prostatic hyperplasia-associated free prostate-specific antigen improves detection of prostate cancer in an artificial neural network
    Carsten Stephan
    Department of Urology and Institute of Medical Informatics, Charite Universitatsmedizin Berlin, Berlin, Germany
    Urology 74:873-7. 2009
    ....
  60. doi request reprint Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma
    Annika Schaefer
    Department of Biology, Free University, Berlin, Germany
    Int J Cancer 126:1166-76. 2010
    ..Thus, differential miRNAs in prostate cancer are useful diagnostic and prognostic indicators. This study provides a solid basis for further functional analyses of miRNAs in prostate cancer...
  61. doi request reprint Germ cell tumors of the gonads: a selective review emphasizing problems in drug resistance and current therapy options
    Mark Schrader
    Department of Urology, Charite Universitatsmedizin, Freie Universitat Berlin, Berlin, Germany
    Oncology 76:77-84. 2009
    ..This review article summarizes theoretical models for the high chemotherapy sensitivity of germ cell tumors and points out new therapeutic prospects...
  62. ncbi request reprint Internal validation of an artificial neural network for prostate biopsy outcome
    Carsten Stephan
    Department of Urology, Charite Universitatsmedizin Berlin, Berlin, Germany
    Int J Urol 17:62-8. 2010
    ..To carry out an internal validation of the retrospectively trained artificial neural network (ANN) 'ProstataClass'...
  63. ncbi request reprint Extraperitoneal radical cystectomy with extraperitonealization of the ileal neobladder: a comparison to the transperitoneal technique
    Florian Jentzmik
    Department of Urology, Charite Universitatsmedizin Berlin, Chariteplatz 1, 10117, Berlin, Germany
    World J Urol 28:457-63. 2010
    ..This retrospective study compares the results of the two procedures with a focus on the peri- and postoperative course...
  64. ncbi request reprint Differential expression of matrix metalloproteinases and their tissue inhibitors in human primary cultured prostatic cells and malignant prostate cell lines
    Ju Zhang
    Department of Urology, University Hospital Charite, Humboldt University Berlin, Berlin, Germany
    Prostate 50:38-45. 2002
    ..The aim was to investigate the expression of matrix metalloproteinases (MMPs), membrane type MMPs (MT-MMPs), and their inhibitors (TIMPs) in human primary cultured prostatic cells and malignant prostate cell lines...
  65. ncbi request reprint Matrix metalloproteinase inhibitor Ro 28-2653 in combination with estramustine: tumor-reducing effects on hormone-sensitive prostate cancer in rats
    Claudia Abramjuk
    Department of Urology, University Hospital Charite, Humboldt University Berlin, Germany
    Anticancer Drugs 16:855-61. 2005
    ..The new MMP inhibitor Ro 28-2653 reduces tumor growth and provides a compatible therapeutic alternative for patients with prostate cancer...
  66. ncbi request reprint Plasma matrix metalloproteinase 9 as biomarker of prostate cancer progression in Dunning (Copenhagen) rats
    Klaus Jung
    Department of Urology, University Hospital Charite, Humboldt University Berlin, Berlin, Germany
    Prostate 54:206-11. 2003
    ..The objective of this study was to assess MMPs in plasma of Dunning tumor rats as indicators of the progression of prostate cancer and follow-up parameters after treatment...
  67. ncbi request reprint Magnetic fluid hyperthermia (MFH)reduces prostate cancer growth in the orthotopic Dunning R3327 rat model
    Manfred Johannsen
    Department of Urology, Charite University Medicine, Campus Mitte, Berlin, Germany
    Prostate 64:283-92. 2005
    ..To confirm these results and evaluate the potential of MFH as a minimally invasive treatment of prostate cancer we carried out a systematic analysis of the effects of MFH in the orthotopic Dunning R3327 tumor model of the rat...
  68. ncbi request reprint Evaluation of magnetic fluid hyperthermia in a standard rat model of prostate cancer
    Manfred Johannsen
    Department of Urology, University Hospital Charité Campus Mitte, Humboldt University, Berlin, Germany
    J Endourol 18:495-500. 2004
    ..To examine the feasibility and potential of magnetic fluid hyperthermia (MFH) as a minimally invasive method for hyperthermia treatment of prostate cancer...
  69. ncbi request reprint Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications
    Klaus Jung
    Department of Urology, University Hospital Charite, Humboldt University of Berlin, Berlin, Germany
    Int J Cancer 111:783-91. 2004
    ..Thus, the importance of serum OPG in detecting bone metastatic spread, alone or in combination with other bone markers, and predicting survival in PCa patients has been clearly demonstrated...
  70. ncbi request reprint Increased cell-free DNA in plasma of patients with metastatic spread in prostate cancer
    Klaus Jung
    Department of Urology, University Hospital Charite, Humboldt University, Schumannstrasse 20 21, D 10098 Berlin, Germany
    Cancer Lett 205:173-80. 2004
    ..It can be concluded that plasma DNA has a limited validity as metastatic marker in PCa patients but follow-up studies combined with the investigation of tumor-related characteristics of plasma DNA would be reasonable...
  71. ncbi request reprint Serum osteoprotegerin and receptor activator of nuclear factor-kappa B ligand as indicators of disturbed osteoclastogenesis in patients with prostate cancer
    Klaus Jung
    Department of Urology, University Hospital Charite, Humboldt University, Berlin, Germany
    J Urol 170:2302-5. 2003
    ..We evaluated the behavior and diagnostic usefulness of the osteoclastogenesis proteins osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) in the serum of patients with prostate cancer (PCa)...
  72. ncbi request reprint Semi-quantitative immunochromatographic test for prostate specific antigen in whole blood: tossing the coin to predict prostate cancer?
    Frank Oberpenning
    Department of Urology, University of Munster, Albert Schweitzer Str 33, D 48129, Munster, Germany
    Eur Urol 43:478-84. 2003
    ..A strip test for the semi-quantitative determination of prostate specific antigen (PSA) based on whole blood was evaluated by the Working Group on Laboratory Diagnostics of the German Urological Association...
  73. ncbi request reprint mRNA expression of the five membrane-type matrix metalloproteinases MT1-MT5 in human prostatic cell lines and their down-regulation in human malignant prostatic tissue
    Monika Jung
    Department of Urology, University Hospital Charite, Humboldt University Berlin, Berlin, Germany
    Prostate 55:89-98. 2003
    ....
  74. ncbi request reprint Multicenter evaluation of an artificial neural network to increase the prostate cancer detection rate and reduce unnecessary biopsies
    Carsten Stephan
    Department of Urology, University Hospital Charite, Humboldt University, D 10098 Berlin, Germany
    Clin Chem 48:1279-87. 2002
    ....
  75. ncbi request reprint An artificial neural network considerably improves the diagnostic power of percent free prostate-specific antigen in prostate cancer diagnosis: results of a 5-year investigation
    Carsten Stephan
    Department of Urology, University Hospital Charite, Humboldt University, Berlin, Germany
    Int J Cancer 99:466-73. 2002
    ..For PSA 4-10 ng/mL, we recommend a first-time biopsy based on the ANN at the 90% sensitivity level. Use of an ANN enhances the %fPSA performance to further reduce the number of unnecessary biopsies within the PSA range 2-10 ng/ml...
  76. ncbi request reprint New insights into the diagnostic accuracy of complexed and total prostate specific antigen using discordance analysis characteristics
    Klaus Jung
    Department of Urology, University Hospital Charite, Berlin, Bayer Vital GmbH, Leverkusen, and ACOMED Statistics, Leipzig, Germany
    J Urol 175:1275-80. 2006
    ..To overcome the biases due to analysis of subgroups selected by concentration ranges of only 1 marker the novel approach named discordance analysis characteristics is presented...
  77. ncbi request reprint A (-5, -7) proPSA based artificial neural network to detect prostate cancer
    Carsten Stephan
    Department of Urology, Universitätsmedizin Charité Berlin, CCM, Germany
    Eur Urol 50:1014-20. 2006
    ..This study reports on the combined use of proPSA within a %free PSA based ANN to enhance specificity of PCa...
  78. ncbi request reprint Diagnostic and prognostic validity of serum bone turnover markers in metastatic renal cell carcinoma
    Klaus Jung
    Department of Urology, University Hospital Charite, Humboldt University of Berlin, Berlin, Germany
    J Urol 176:1326-31. 2006
    ..We assessed the diagnostic accuracy of bone markers in the serum of patients with renal cell carcinoma to detect bone metastases and evaluate the prognostic potential concerning renal cell carcinoma caused mortality...
  79. ncbi request reprint Electrophoretic subforms of free prostate-specific antigen in serum as promising diagnostic tool in prostate cancer diagnostics
    Klaus Jung
    Department of Urology, University Hospital Charite, University Medicine Berlin, Berlin, Germany
    Urology 69:320-5. 2007
    ....
  80. ncbi request reprint PSA and new biomarkers within multivariate models to improve early detection of prostate cancer
    Carsten Stephan
    Department of Urology, Charite Universitatsmedizin Berlin, Campus Charite Mitte, Chariteplatz 1, D 10098 Berlin, Germany
    Cancer Lett 249:18-29. 2007
    ..There is also positive impact of tPSA and fPSA assays on the outcome of ANNs. New markers provide additional value within ANNs but to prove their clinical usefulness further testing is necessary...
  81. ncbi request reprint The ratio of prostate-specific antigen (PSA) to prostate volume (PSA density) as a parameter to improve the detection of prostate carcinoma in PSA values in the range of < 4 ng/mL
    Carsten Stephan
    Department of Urology, University Hospital Charite Berlin, Berlin, Germany
    Cancer 104:993-1003. 2005
    ..Possible cut-off levels depending on the tPSA should be established...
  82. ncbi request reprint Different prostate-specific antigen assays give different results on the same blood sample: an obstacle to recommending uniform limits for prostate biopsies
    Carsten Stephan
    Department of Urology, Charite Universitatsmedizin Berlin, CCM, Germany
    BJU Int 99:1427-31. 2007
    ..To show the effect of different results for total prostate specific antigen (tPSA) and percentage free/total PSA (%fPSA) obtained with different assays for differentiating between benign and malignant prostate diseases...
  83. ncbi request reprint Fast-track surgery in laparoscopic radical prostatectomy: basic principles
    O Gralla
    Department of Urology, Campus Mitte, Charite Universitatsmedizin Berlin, Schumannstrasse 20 21, 10117 Berlin, Germany
    World J Urol 25:185-91. 2007
    ..Thus, fast-track concepts might contribute to saving resources in the long term. However, more evidence based on larger prospective trials is needed to achieve optimal quality of life for patients perioperatively...
  84. doi request reprint [MicroRNA in uro-oncology : New hope for the diagnosis and treatment of tumors?]
    A Schaefer
    Klinik für Urologie, Charite Universitatsmedizin, Berlin, Deutschland
    Urologe A 48:877-85. 2009
    ..A systematic elucidation of characteristic miRNA abnormalities could decisively improve diagnostics as well as therapy of urological tumors...
  85. ncbi request reprint Serum amyloid A as indicator of distant metastases but not as early tumor marker in patients with renal cell carcinoma
    Azizbek Ramankulov
    Department of Urology, Charite University Medicine Berlin, Campus Charite Mitte, Schumannstr 20 21, 10117 Berlin, Germany
    Cancer Lett 269:85-92. 2008
    ..86. SAA was identified as a significant independent factor of survival in RCC patients using the multivariate Cox proportional hazards regression model. SAA could be a useful analyte in predicting the survival outcome of RCC patients...
  86. ncbi request reprint [Clinical pathway "laparoscopic prostatectomy". Analysis of anesthesiological procedures in a randomized study]
    J P Braun
    Klinik fur Anasthesiologie und Operative Intensivmedizin, Charite Universitatsmedizin, Campus Mitte, Schumannstrasse 20 21, 10117 Berlin
    Anaesthesist 54:1186-96. 2005
    ..During this module the indicators of quality such as vigilance, pain, postoperative nausea and vomiting (PONV) and mobilization were measured. Costs were evaluated and analyzed by a bottom-up procedure...
  87. ncbi request reprint Body size and weight as predisposing factors in varicocele
    M May
    Department of Urology, Carl Thiem Hospital Cottbus, Cottbus, Germany
    Scand J Urol Nephrol 40:45-8. 2006
    ..The aim of this investigation was to examine a possible influence of weight, height and body mass index (BMI) on the formation of varicoceles during childhood and adolescence...
  88. ncbi request reprint Osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) in the serum of healthy adults
    K Jung
    Department of Urology, University Hospital Charite, Humboldt University Berlin, Germany
    Int J Biol Markers 17:177-81. 2002
    ..As new, sensitive ELISAs have been developed recently, reference serum ranges should be established to use these analytes for possible diagnostic purposes...
  89. ncbi request reprint Transrectal broadband-Doppler sonography with intravenous contrast medium administration for prostate imaging and biopsy in men with an elevated PSA value and previous negative biopsies
    Kasra Taymoorian
    Departments of Urology, Charite, Universitatsmedizin Berlin, Germany
    Anticancer Res 27:4315-20. 2007
    ..THE AIM of this study was to determine the prostate cancer detection rate of targeted biopsy using contrast-enhanced ultrasound (US) in patients with elevated prostate specific antigen (PSA) levels and previous negative biopsy...
  90. ncbi request reprint PSA and other tissue kallikreins for prostate cancer detection
    Carsten Stephan
    Department of Urology, Charite Universitatsmedizin Berlin, Berlin, Germany
    Eur J Cancer 43:1918-26. 2007
    ..These new findings may add substantial clinical information for early detection of prostate cancer...
  91. ncbi request reprint Differential gene expression of urokinase-type plasminogen activator and its receptor in human renal cell carcinoma
    Venugopal Bhuvarahamurthy
    Department of Urology, University Hospital Charite, Humboldt University Berlin, D 10098 Berlin, Germany
    Oncol Rep 14:777-82. 2005
    ..We conclude that uPA- and uPAR are overexpressed in RCC and could function as tumour markers...
  92. ncbi request reprint Photodynamic therapy of prostate cancer by means of 5-aminolevulinic acid-induced protoporphyrin IX - in vivo experiments on the dunning rat tumor model
    Dirk Zaak
    Department of Urology, Ludwig Maximilians University, Munich, Germany
    Urol Int 72:196-202. 2004
    ....
  93. ncbi request reprint Different mRNA and protein expression of matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 in benign and malignant prostate tissue
    Ralf Lichtinghagen
    Department of Clinical Chemistry, University Medical School, Hannover, Germany
    Eur Urol 42:398-406. 2002
    ..The aim of this study was to assess the behavior of the matrix metalloproteinases (MMPs) 2 and 9 and the tissue inhibitor of metalloproteinases 1 (TIMP-1) in human prostate cancer...
  94. ncbi request reprint Free PSA forms in prostatic tissue and sera of prostate cancer patients: analysis by 2-DE and western blotting of immunopurified samples
    Glòria Tabarés
    Roche Diagnostics GmbH, Nonnenwaldstr 2, 82372 Penzberg, Germany
    Clin Biochem 40:343-50. 2007
    ....
  95. ncbi request reprint mRNA expression profile of matrix metalloproteinases and their tissue inhibitors in malignant and non-malignant prostatic tissue
    Ralf Lichtinghagen
    Department of Clinical Chemistry, University Medical School, Hannover, Germany
    Anticancer Res 23:2617-24. 2003
    ..Increased expression of matrix metalloproteinases (MMPs) was found in various carcinomas. The aim of this study was to present a comprehensive mRNA expression profile of MMPs in benign and malignant prostatic tissue...
  96. doi request reprint Re: Al-Azab R, Toi A, Lockwood G, et al. Prostate volume is strongest predictor of cancer diagnosis at transrectal ultrasound-guided prostate biopsy with prostate-specific antigen values between 2.0 and 9.0 ng/mL (Urology 69:103-107, 2007)
    Carsten Stephan
    Urology 72:951. 2008
  97. ncbi request reprint Circulating matrix metalloproteinase-7: an early or metastatic marker for renal cell carcinoma?
    Klaus Jung
    Clin Chem 54:1927-9. 2008
  98. ncbi request reprint Re: Felix K.-H. Chun, Markus Graefen, Alberto Briganti, Andrea Gallina, Julia Hopp, Michael W. Kattan, Hartwig Huland and Pierre I. Karakiewicz. Initial biopsy outcome prediction--head-to-head comparison of a logistic regression-based nomogram versus arti
    Carsten Stephan
    Eur Urol 51:1446-7; author reply 1448. 2007
  99. ncbi request reprint Discordance analysis characteristics as a new method to compare the diagnostic accuracy of tests: example of complexed versus total prostate-specific antigen
    Thomas Keller
    ACOMED Statistik, Leipzig, Germany
    Clin Chem 51:532-9. 2005
    ..We developed a new approach, which we have named discordance analysis characteristics (DAC)...
  100. ncbi request reprint Lycopene effects on rat normal prostate and prostate tumor tissue
    Ulrich Siler
    DSM Nutritional Products Ltd, Human Nutrition and Health, Basel, Switzerland
    J Nutr 135:2050S-2S. 2005
  101. ncbi request reprint Laparoscopic surgery versus antegrade scrotal sclerotherapy: Retrospective comparison of two different approaches for varicocele treatment
    Matthias May
    Department of Urology, Carl Thiem Hospital, Cottbus, Germany
    Eur Urol 49:384-7. 2006
    ..However, very limited data comparing these two approaches are available in the literature. We present our experience regarding outcome and complications with each treatment modality...